Pancreatic Metastasis from Gastrointestinal Stromal Tumor of the Stomach: A Case Report

Nobutoshi Hagiwara, Takeshi Matsutani, Tsutomu Nomura, Itsuo Fujita, Yoshikazu Kanazawa, Junji Ueda, Hiroki Arai, Daisuke Kakinuma, Hitoshi Kanno, Zenya Naito and Eiji Uchida

1Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan
2Department of Pathology and Integrative Oncological Pathology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan

We report the first documented case of pancreatic metastasis from a gastrointestinal stromal tumor of the stomach. A 42-year-old Japanese man presented with severe abdominal discomfort. Computed tomography of the abdomen showed a huge heterogeneous mass consisting of cystic and solid components in the left upper abdomen. 18F-Fluorodeoxyglucose positron-emission tomography revealed high tracer uptake in the abdominal mass. After total gastrectomy with lymphnodectomy was performed, a hard mass was palpated in the pancreatic tail. The pancreatic tumor was also resected under the therapeutic strategy. Histological examinations of the resected gastric and pancreatic specimens revealed that both tumors consisted of uniform spindle cells with a fascicular growth pattern and were immunohistochemically positive for CD34 and CD117/KIT. Gene sequencing analysis of DNA from each tumor revealed an identical deletion of 21 nucleotides in exon 11 of the gene KIT. On the basis of these results, we concluded that the pancreatic tumor was a metastatic tumor from the gastrointestinal stromal tumor of the stomach. (J Nippon Med Sch 2016; 83: 133-138)

Key words: gastrointestinal stromal tumor, stomach, pancreatic metastasis, gene sequencing analysis

Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract but are rarely malignant tumors of the digestive tract, accounting for 0.1% to 3.0% of all gastrointestinal neoplasms1-5. Gastric GISTs metastasize most often to the liver and peritoneum but rarely to the pancreas, but a solitary pancreatic metastasis is extremely difficult to differentiate from a primary pancreatic GIST. To our knowledge, surgical resection of a solitary pancreatic metastasis from a GIST has not previously been reported. We describe the first documented case of pancreatic metastasis from a GIST of the stomach.

Report of a Case
A 42-year-old Japanese man was admitted to our hospital because of severe abdominal discomfort. His medical and family histories were unremarkable. On physical examination, a huge, elastic, hard mass was palpable in the left hypochondriac region. The results of laboratory tests were within normal ranges.

Double-contrast barium gastrography showed a well-demarcated filling defect in the greater curvature of the gastric body (Fig. 1a). Computed tomography of the abdomen with intravenous contrast material revealed a huge heterogeneous mass, approximately 15 cm in greatest diameter, containing cystic and solid components in the left upper quadrant of the abdomen. The mass compressed the spleen and the pancreas (Fig. 1b). Positron emission tomography revealed high uptake of 18F-fluorodeoxyglucose in the left upper quadrant, with standardized uptake values of 9.0 and 2.9, respectively (Fig. 1c). Upper gastrointestinal endoscopy revealed a narrowed gastric lumen with normal gastric mucosa. Endoscopic ultrasonography showed a heterogeneous hypoechoic tumor that had arisen from the muscularis
Gastrography showed a large filling defect on the posterior wall of the gastric body (black arrows) (a). A preoperative, postcontrast, computed tomographic scan of the abdomen shows a large heterogeneous lesion occupying most of the left upper quadrant of the abdominal cavity (b). An 18F-fluorodeoxyglucose-positron emission tomographic image shows considerable 18F-fluorodeoxyglucose accumulation in the large heterogeneous lesion at the same level as shown by the computed tomographic scan (c).

Fig. 1

Macroscopic findings of the resected specimen. A huge submucosal tumor developed on the posterior wall of the stomach as an extrinsic tumor. A solid tumor arising in the pancreatic tail was unexposed on the surface of the pancreas.

Fig. 2

Properia in the body of the stomach. We strongly suspected that the tumor was a primary GIST of the stomach.

To eliminate the severe symptoms of abdominal fullness, tumor resection was indicated as an emergency oncological treatment. On intraoperative abdominal exploration, the tumor was found to have arisen from the posterior wall of the stomach, with no apparent invasion of adjacent organs. Total gastrectomy with lymphnodectomy was performed without tumor rupture.

After the huge gastric tumor was removed, a hard, solid mass was palpated in the tail of the pancreas and suspected to be a malignant tumor. Distal pancreatectomy with splenectomy was therefore performed. Macroscopic examination of the resected specimen showed a large, irregular gastric mass, measuring 19 × 23 cm and extending mainly from the greater curvature to the posterior gastric wall of the stomach (Fig. 2). The surface of the pancreatic tumor was covered by grossly normal pancreatic parenchyma.

Pathological examination of the resected specimens stained with hematoxylin and eosin revealed that the gastric tumor consisted of uniform spindle cells with a fascicular growth pattern (Fig. 3a). The gastric tumor had a high mitotic index (greater than 5 mitoses per 50 high-power fields) and a high proliferation index (Ki-67/MIB-1 > 10%). Immunohistochemical examinations revealed that the tumor cells were positive for CD34 and CD117/KIT (Fig. 3b, c) and negative for α-smooth muscle actin and S-100 protein. These pathological features were consistent with those of the GIST of the stomach. The pan-
Pancreatic Metastasis from Gastrointestinal Stromal Tumor

Fig. 3  Histopathological findings of the gastric tumor. The tumor consisted of uniform spindle cells with a fascicular growth pattern (a). (hematoxylin and eosin, ×400) Immunohistochemical examination reveals diffusely positive staining for CD34 (b) and CD117/KIT (c) (CD34, ×400; CD117/KIT, ×400).

Fig. 4  Histopathological findings of the pancreatic tumor. The tumor was a well-circumscribed round lesion surrounded by normal pancreatic tissue in the pancreatic parenchyma (a, b). The tumor was positive for CD34 and CD117/KIT (c, d).

The gastric tumor also showed similar spindle cells after being stained with hematoxylin and eosin and was well circumscribed and surrounded by normal pancreatic parenchyma (Fig. 4a, b). The pancreatic tumor was positive for both CD34 and CD117/KIT (Fig. 4c, d) and was negative for Wilms’ tumor 1, cytokeratin, and pancreatic endocrine markers, such as glucagon, insulin, gastrin, and somatostatin.

So that molecular biological examinations could be performed for differential diagnosis, the specific cells positive for CD34 and CD117/KIT were isolated from microscopic regions of both tumor specimens with microdissection techniques. The DNA isolated from each tumor underwent mutational analyses of exons 9, 11, 13, and 17 of the gene KIT and exons 12 and 18 of the gene PDGFRA (platelet derived growth factor receptor alpha), known as common mutational hotspots for GIST, to identify gene variants. An identical deletion of 21 nucleotides (c. 1656–1675 del21GTATGAAGTACAGTGGAAGGT) in exon 11 of KIT was detected in DNA from both tumors. The mutation was absent from uninvolved tissue of the patient (Fig. 5a, b, c). The gene sequencing analysis revealed that both the gastric and pancreatic tumor cells possessed an identical somatic mutation.

The postoperative course was uneventful. Postoperative adjuvant chemotherapy (imatinib mesylate, 400 mg/
Fig. 5  A DNA sequence of chromosome in exon 11 of KIT gene shows wild type DNA sequence (a) and identical deletion of 21 nucleotides (c.1656–1675 del21 GTATGAAGTACAGTGGAAGGT) in exon 11 in both gastric tumor DNA (b) and pancreatic tumor DNA (c).

day) was started 1 month after surgery. The patient has survived for more than 48 months after surgery without any evidence of recurrence or disease progression and continues to receive imatinib mesylate.

Discussion

The GISTs are known for their tendency to metastasize by way of both intraperitoneal dissemination and hematogenous routes\(^6,7\). The most common hematogenous metastatic site of GISTs is the liver\(^8\). In contrast, the pancreas is not a common site of metastasis from a GIST of the stomach. We found no previously reported case of GIST metastatic to the pancreas in a MEDLINE search with the key words “gastrointestinal stromal tumor,” “pancreatic metastasis,” and “pancreas metastasis.”

Metastatic tumors account for less than 2% of all pancreatic malignancies. The most common primary origins of metastases to the pancreas are renal cell carcinoma (62.6%); carcinomas of the colon (6.2%), lung (4%), and ovary (4.7%); sarcoma (7.2%); and melanoma of the skin (4%)\(^9,10\). However, a previous study has found that at autopsy the most common primary tumor site of metastases to the pancreas is the stomach\(^11\). In 2014 a retrospective study of 22 patients found that the malignancy most commonly metastasizing to the pancreas was gastric carcinoma\(^12\). Therefore, gastric malignancies may metastasize to the pancreas more frequently than previously thought.

Histopathological examination of the gastric and pancreatic tumors in our patient revealed similar spindle cells that were diffusely positive for the GIST immunohistochemical markers CD34 and CD117/KIT. A primary GIST arising in the pancreas has been reported as an extragastrointestinal stromal tumor or extra-GIST\(^13\), and primary pancreatic tumors often cannot be differentiated...
from metastatic tumors with currently available histopathological methods. We analyzed DNA sequences to investigate the genetic characteristics of both tumors and found an identical mutational pattern in exon 11 of KIT in DNA from both the gastric tumor and the pancreatic tumor. The molecular pathogenesis of GIST has generally been considered to result from expansion of a cell clone that has acquired an activating mutation in the KIT proto-oncogene\(^1\). A recent investigation of genetic mutations in primary and metastatic tumor cells has found that paired samples of primary colorectal cancer and metastases show consistent mutation patterns upon the mutational analysis of the gene KRAS (Kirsten rat sarcoma viral oncogene homolog)\(^2\). These findings support the notion that the primary GIST tumor and the metastatic pancreatic tumor in our patient had identical origins. On the basis of a comprehensive analysis of these clinical and biological factors, we concluded that the pancreatic tumor was a metastatic tumor from the GIST of the stomach.

Local recurrence and distant metastases have been reported to develop in more than 30% of patients with high-risk GIST despite apparently complete resection\(^3\). Most recurrences or metastases occurring after resection with a R0 margin of a high-risk GIST appear within 3 years after primary surgery. Adjuvant therapy with imatinib mesylate, a specific molecular inhibitor, is beneficial after the primary GIST is resected. Three years of adjuvant treatment with imatinib mesylate has been shown to improve recurrence-free survival and overall survival in patients with high-risk GISTs\(^4\). However, tumor sensitivity to imatinib has been reported to differ according to the location of the mutation\(^5\). The GISTs with exon 11 mutations of KIT are more than 10 times as sensitive to imatinib than are GISTs with mutations in other exons\(^6\). Identification of the causative mutation before starting imatinib treatment is thus considered clinically and economically beneficial in patients with GIST\(^7\). In our patient, both the gastric and pancreatic GISTs had mutations of exon 11 in the KIT gene. The tumors were therefore expected to be sensitive to imatinib treatment. The patient has shown no sign of recurrence or disease progression for more than 4 years after surgery and continues to receive adjuvant treatment with imatinib.

In conclusion, we have reported an extremely rare case of gastric GIST with synchronous pancreatic metastasis that successfully responded to multimodality therapy. Our findings may be helpful for determining a multimodality treatment strategy and for developing new treatment options for a case of GIST with such unusual metastases.

Conflict of Interest: The authors have no conflicts of interest to declare.

References

17. Eisenberg BL: The SSG XVIII/AIO trial: results change...


(Received, October 25, 2015)  
(Accepted, February 3, 2016)